CHESS/ETOP 14-18: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic nonsmall cell lung cancer
Indication :

Synchronous oligo-metastatic non small cell lung cancer


Sponsor :

ETOP


Phase :

II


Ligne :

First Line


Traitement :

Durvalumab + Carboplatin/Paclitaxel + metastasis SBRT followed by definitive surgery or radiotherapy to the primary tumor.


Site :

CHUV, HUG


Contact(s) :
Alfredo ADDEO
Principal Investigator

HUG
Oncology

Rue Gabrielle Perret-Gentil, 4
1211
Geneva

+41795535035
Alfredo.Addeo@hcuge.ch
Ludiwine Aeby
Study Coordinator

HUG
Oncology

Rue Gabrielle Perret-Gentil, 4
1211
Geneva

+41795531182
ludiwine.aeby@hcuge.ch
Solange Peters
Investigateur principal

CHUV
Département d'Oncologie - Service d'oncologie médicale

Rue du Bugnon 46
Lausanne
1011

+41795560192
solange.peters@chuv.ch

Primary objective :

To evaluate PFS in synchronous oligometastatic NSCLC patients treated with induction immunotherapy, chemotherapy and SBRT to all metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour.


Inclusion criteria :
  • Histologically confirmed non-small cell lung cancer
  • Synchronous oligo-metastatic stage IV disease: maximum of three distant metastases, one of which must be extra-cerebral for stereotactic body radiotherapy (SBRT); Initial mediastinal staging is recommended (except for lymph nodes <1 cm on CT and PET-negative) preferentially by endobronchial ultrasound (EBUS); Neurosurgical resection of one single central nervous system (CNS) metastasis or laparoscopic resection of one adrenal metastasis before study inclusion is allowed (one extra-cerebral metastasis must be available for SBRT)
  • Able to understand and give written informed consent and comply with study procedures
  • Age ≥18 years
  • ECOG Performance Status 0-1
  • Availability of tumour tissue for translational research
  • Adequate haematological, renal and liver function

Exclusion criteria :
  • Prior chemotherapy, radiotherapy or therapeutic surgery for NSCLC (an exception is the resection of one single CNS or adrenal metastasis, as above)
  • Activating driver mutation: epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene receptor tyrosine kinase (ROS1)
  • More than three distant metastases
  • Brain metastases not amendable for radiosurgery or neurosurgery
  • Extracranial metastatic locations such as malignant ascites, pleural or pericardial effusion, diffuse lymphangitiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques.
  • Primary lung cancer not suitable for radical therapy (pneumonectomy excluded)
  • History of leptomeningeal carcinomatosis
  • Major surgery or significant traumatic injury from which the patient has not recovered at least 28 days before enrolment
  • Any uncontrolled intercurrent illness, including but not limited to: ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease or serious chronic gastrointestinal conditions associated with diarrhea, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol
  • Active tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
  • Active autoimmune disease requiring systemic treatment
  • Severe or uncontrolled cardiac disease requiring treatment
  • History of primary immunodeficiency
  • History of allogeneic organ transplant
  • Receipt of live attenuated vaccines within 30 days prior to enrolment
  • Known allergies or hypersensitivity to trial drugs or to any excipient.
  • Women who are pregnant or in the period of lactation.
  • Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and for up to 90 days after last dose of durvalumab.